Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02247479
Recruitment Status : Terminated
First Posted : September 25, 2014
Results First Posted : April 23, 2019
Last Update Posted : June 26, 2019
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Condition or disease Intervention/treatment Phase
Geographic Atrophy Drug: Lampalizumab Other: Sham Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 906 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Actual Study Start Date : September 18, 2014
Actual Primary Completion Date : January 29, 2018
Actual Study Completion Date : January 29, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Lampalizumab Once in Every 4 Weeks (Q4W)
Participants will receive 10 milligrams (mg) dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
Drug: Lampalizumab
Participants will receive 10 mg dose of lampalizumab administered intravitreally.
Other Name: RO5490249

Experimental: Lampalizumab Once in Every 6 Weeks (Q6W)
Participants will receive 10 mg dose of lampalizumab administered by intravitreal injections for approximately 96 weeks.
Drug: Lampalizumab
Participants will receive 10 mg dose of lampalizumab administered intravitreally.
Other Name: RO5490249

Sham Comparator: Sham Comparator
Participants will receive sham comparator Q4W or Q6W for 96 weeks.
Other: Sham
A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.




Primary Outcome Measures :
  1. Change From Baseline in Geographic Atrophy (GA) Area, as Assessed by Fundus Autofluoresence (FAF) at Week 48 [ Time Frame: Baseline, Week 48 ]
    The change in GA lesion area was measured by FAF and analysis of FAF images was performed by the central reading center. A positive change from baseline indicates an increase in size of GA lesion area (worsening; disease progression).

  2. Change From Baseline in GA Area in Complement Factor I (CFI) Positive and Negative Participants at Week 48 [ Time Frame: Baseline, Week 48 ]
    For CFI profile, positive or negative biomarker status refers to the presence (carrier) or absence of the risk allele at CFI and at least one risk allele at complement factor H (CFH) or risk locus containing both complement component 2 and complement factor B (C2/CFB).The change in GA lesion area was measured by FAF and analysis of FAF images was performed by the central reading center. A positive change from baseline indicates an increase in size of GA lesion area (worsening; disease progression).


Secondary Outcome Measures :
  1. Change From Baseline in Number of Absolute Scotomatous Points as Assessed by Mesopic Micrometry at Week 48 [ Time Frame: Baseline, Week 48 ]
    Scotomatous points were the testing points on microperimetry examination that were centered on the macula and reported a lack of retinal sensitivity within the range tested, a maximum of 68 points were tested within this range. Higher results indicate expansion of absolute scotoma and higher number of abolute scotomatous points. Mesopic microperimetry assessments were performed post-dilation on the study eye only, and the data was forwarded to the central reading center. The data was collected up to Week 48 instead of Week 96, due to early termination of the study. A positive change from baseline indicates an increase in the number of absolute scotomatous points (more lack of retinal sensitivity); disease worsening.

  2. Change From Baseline in Mean Macular Sensitivity as Assessed by Mesopic Microperimetry at Week 48 [ Time Frame: Baseline, Week 48 ]
    Mesopic microperimetry was used to assess macular sensitivity and assessments were performed post-dilation on the study eye only, and the data was forwarded to the central reading center. A negative change from baseline indicates a decrease in the mean macular sensitivity; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.

  3. Change From Baseline in Best Corrected Visual Acuity (BCVA) Score as Assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Week 48 [ Time Frame: Baseline, Week 48 ]
    BCVA score was based on the number of letters read correctly on the ETDRS visual acuity chart assessed at a starting distance of 4 meters (m). BCVA score testing was performed prior to dilating the eyes. BCVA score ranges from 0 to 100 letters in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A negative change from baseline indicates a decrease in the visual acuity; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.

  4. Percentage of Participants With Less Than 15 Letters Loss From Baseline in BCVA Score at Week 48 [ Time Frame: Week 48 ]
    Loss of less than 15 letters from baseline was assessed by the ETDRS chart at a starting distance of 4 meters (m). BCVA was measured using an eye chart and was reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The data was collected up to Week 48 instead of Week 96, due to early termination of the study.

  5. Change From Baseline in Low Luminance Visual Acuity (LLVA) as Assessed by ETDRS Chart Under Low Luminance Conditions at Week 48 [ Time Frame: Baseline, Week 48 ]
    The LLVA was measured by placing a 2.0-log-unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart. The assessment was performed prior to dilating the eyes. LLVA score ranges from 0 to 100 letters in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The data was collected up to Week 48 instead of Week 96, due to early termination of the study.

  6. Percentage of Participants With Less Than 15 Letters Loss From Baseline in LLVA Score at Week 48 [ Time Frame: Week 48 ]
    Loss of less than 15 letters from baseline was assessed by the ETDRS chart at a starting distance of 4 m. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.

  7. Change From Baseline in Binocular Reading Speed as Assessed by Minnesota Low-Vision Reading Test (MNRead) Charts or Radner Reading Charts at Week 48 [ Time Frame: Baseline, Week 48 ]
    MNRead acuity cards were continuous-text reading-acuity cards suitable for measuring the reading acuity and reading speed of normal and low-vision participants. The MNRead acuity cards consisted of single, simple sentences with equal numbers of characters. A stopwatch was used to record time to a tenth of a second. Sentences that could not be read or were not attempted due to vision should be recorded as 0 for time and 10 for errors. The Radner Reading Cards were suitable for measuring reading speed, reading visual acuity, and critical print size. The reading test was stopped when the reading time was longer than 20 seconds or when the participant was making severe errors. A negative change from baseline indicates a decrease in the binocular reading speed; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.

  8. Change From Baseline in Monocular Maximum Reading Speed as Assessed by MNRead Charts or Radner Reading Charts at Week 48 [ Time Frame: Baseline, Week 48 ]
    MNRead acuity cards were continuous-text reading-acuity cards suitable for measuring the reading acuity and reading speed of normal and low-vision participants. The MNRead acuity cards consisted of single, simple sentences with equal numbers of characters. A stopwatch was used to record time to a tenth of a second. Sentences that could not be read or were not attempted due to vision should be recorded as 0 for time and 10 for errors. The Radner Reading Cards were suitable for measuring reading speed, reading visual acuity, and critical print size. The reading test was stopped when the reading time was longer than 20 seconds or when the participant was making severe errors. A negative change from baseline indicates a decrease in the monocular reading speed; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.

  9. Change From Baseline in National Eye Institute Visual Functioning Questionnaire 25-item (NEI VFQ-25) Version Composite Score at Week 48 [ Time Frame: Baseline, Week 48 ]
    NEI-VFQ-25 questionnaire included 25 items based on which overall composite VFQ score and 12 subscales were derived: near activities, distance activities, general health,general vision, ocular pain, vision−specific social functioning, vision−specific mental health, vision−specific role difficulties, vision−specific dependency, driving, color vision and peripheral vision. Response to each question converted to 0-100 score. Each subscale, total score=average of items contributing to score. For each subscale and total score, score range: 0 to 100, a higher score represents better functioning. A negative change from baseline indicates a decrease in the visual functioning; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.

  10. Change From Baseline in NEI VFQ-25 Near Activity Subscale Score at Week 48 [ Time Frame: Baseline, Week 48 ]
    NEI-VFQ-25 questionnaire included 25 items based on which near activities were measured. Near activities are defined as reading ordinary print in newspapers, performing work or hobbies requiring near vision, or finding something on a crowded shelf. Response to each question converted to 0-100 score. Subscale=average of items contributing to score. For this subscale the score range is 0 to 100, a higher score represents better functioning. A negative change from baseline indicates a decrease in the near visual activities; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.

  11. Change From Baseline in NEI VFQ-25 Distance Activity Subscale Score at Week 48 [ Time Frame: Baseline, Week 48 ]
    NEI-VFQ-25 questionnaire included 25 items based on which distance activities were measured. Distance activities are defined as reading street signs or names on stores, and going down stairs, steps, or curbs. Response to each question converted to 0-100 score. Subscale=average of items contributing to score. For this subscale the score range is 0 to 100, a higher score represents better functioning. A negative change from baseline indicates a decrease in the distance visual activities; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.

  12. Change From Baseline in Mean Functional Reading Independence (FRI) Index at Week 48 [ Time Frame: Baseline, Week 48 ]
    The FRI was an interviewer-administered questionnaire with 7 items on functional reading activities most relevant to GA AMD participants. It has one total index score. For each FRI Index reading activity performed in the past 7 days, participants were asked about the extent to which they required vision aids, adjustments in the activity, or help from another participant. Mean FRI Index scores range from 1 to 4, with higher scores indicating greater independence. A negative change from baseline indicates a decrease in the FRI; disease worsening. The data was collected up to Week 48 instead of Week 96, due to early termination of the study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Well demarcated area(s) of Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) with no evidence of prior or active choroidal neovascularization (CNV) in both eyes

Exclusion Criteria:

Ocular Exclusion Criteria: Study Eye

  • History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD
  • Previous laser photocoagulation for CNV, diabetic macular edema, retinal vein occlusion, and proliferative diabetic retinopathy
  • Previous intravitreal drug delivery (intravitreal corticosteroid injection, anti-angiogenic drugs, anti-complement agents, or device implantation) Ocular Exclusion Criteria: Both Eyes
  • GA in either eye due to causes other than AMD
  • Previous treatment with eculizumab, lampalizumab and/or fenretinide

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02247479


Locations
Hide Hide 145 study locations
Layout table for location information
United States, Alabama
Uni of Alabama At Birmingham Clinical Research Unit
Birmingham, Alabama, United States, 35233
United States, Arizona
Retinal Research Institute, LLC
Phoenix, Arizona, United States, 85014
Retina Centers P.C.
Tucson, Arizona, United States, 85704
United States, California
California Retina Consultants
Bakersfield, California, United States, 93309
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States, 90211
The Gavin Herbert Eye Institute - UC, Irvine
Irvine, California, United States, 92697-4375
Jules Stein Eye Institute/ UCLA
Los Angeles, California, United States, 90095-7000
East Bay Retina Consultants
Oakland, California, United States, 94609
Southern CA Desert Retina Cons
Palm Desert, California, United States, 92211
W Coast Retina Med Group Inc
San Francisco, California, United States, 94107
UCSF; Ophthalmology
San Francisco, California, United States, 94143
Orange County Retina Med Group
Santa Ana, California, United States, 92705
California Retina Consultants
Santa Barbara, California, United States, 93103
United States, Florida
Florida Eye Microsurgical Inst
Boynton Beach, Florida, United States, 33426
National Ophthalmic Research Institute
Fort Myers, Florida, United States, 33912
Florida Eye Associates
Melbourne, Florida, United States, 32901
Retina Care Specialists
Palm Beach Gardens, Florida, United States, 33410
Bascom Palmer Eye Institute
Palm Beach Gardens, Florida, United States, 33418
Retina Specialty Institute
Pensacola, Florida, United States, 32503
Fort Lauderdale Eye Institute
Plantation, Florida, United States, 33324
Retina Vitreous Assoc of FL
Saint Petersburg, Florida, United States, 33711
Southern Vitreoretinal Assoc
Tallahassee, Florida, United States, 32308
Retina Associates of Florida, LLC
Tampa, Florida, United States, 33609
United States, Georgia
Southeast Retina Center
Augusta, Georgia, United States, 30909
Georgia Retina PC
Marietta, Georgia, United States, 30060
United States, Hawaii
Retina Consultants of Hawaii
'Aiea, Hawaii, United States, 96701
United States, Illinois
Northwestern Medical Group/Northwestern University
Chicago, Illinois, United States, 60611
University Retina and Macula Associates, PC
Oak Forest, Illinois, United States, 60452
United States, Indiana
Midwest Eye Institute Northside
Indianapolis, Indiana, United States, 46290
United States, Iowa
Wolfe Eye Clinic
West Des Moines, Iowa, United States, 50266
United States, Kansas
Retina Associates
Shawnee Mission, Kansas, United States, 66204
United States, Kentucky
Lahey Clinic Med Ctr
Lexington, Kentucky, United States, 02421
Retina Associates of Kentucky
Lexington, Kentucky, United States, 40509
United States, Maine
Maine Eye Center
Portland, Maine, United States, 04101
United States, Maryland
Retina Specialists
Towson, Maryland, United States, 21204
United States, Massachusetts
Tufts Medical Center Research
Boston, Massachusetts, United States, 02111
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States, 02114
Vitreo-Retinal Associates, PC
Worcester, Massachusetts, United States, 01605
United States, Michigan
Vitreo-Retinal Associates
Grand Rapids, Michigan, United States, 49546
Specialty Eye Institute
Jackson, Michigan, United States, 49202
Assoc Retinal Consultants PC
Royal Oak, Michigan, United States, 48073
Retina Consultants of Michigan
Southfield, Michigan, United States, 48034
United States, Nebraska
Eye Surgical Associates
Lincoln, Nebraska, United States, 68506
United States, Nevada
Retina Consultants of Nevada
Las Vegas, Nevada, United States, 89123
United States, New Jersey
Retina Center of New Jersey
Bloomfield, New Jersey, United States, 07003
New Jersey Retina Research Foundation
Edison, New Jersey, United States, 08820
Delaware Valley Retina Assoc
Lawrenceville, New Jersey, United States, 08648
United States, New York
Long Is. Vitreoretinal Consult
Hauppauge, New York, United States, 11788
Opthalmic Consultants of LI
Lynbrook, New York, United States, 11563
New York Eye & Ear Infirmary
New York, New York, United States, 10003
Retina Consultants of Western New York
Orchard Park, New York, United States, 14127
Retina Vit Surgeons/Central NY
Syracuse, New York, United States, 13224
United States, North Carolina
Western Carolina Retinal Associate PA
Asheville, North Carolina, United States, 28803
Wake Forest Baptist Health Eye Centre
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Retina Assoc of Cleveland Inc
Beachwood, Ohio, United States, 44122
Cleveland Clinic Foundation; Cole Eye Institute
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
Retina Vitreous Consultants
Monroeville, Pennsylvania, United States, 15146
Associates in Ophthalmology
West Mifflin, Pennsylvania, United States, 15122
United States, South Carolina
Charleston Neuroscience Inst
Ladson, South Carolina, United States, 29456
United States, Tennessee
Tennessee Retina PC.
Nashville, Tennessee, United States, 37203
Vanderbilt
Nashville, Tennessee, United States, 37232
United States, Texas
Retina Res Institute of Texas
Abilene, Texas, United States, 79606
Texas Retina Associates
Arlington, Texas, United States, 76012
Austin Retina Associates
Austin, Texas, United States, 78705
Retina Research Center
Austin, Texas, United States, 78705
UT Southwestern MC at Dallas
Dallas, Texas, United States, 75390
Valley Retina Institute P.A.
McAllen, Texas, United States, 78503
Strategic Clinical Research Group, LLC
Willow Park, Texas, United States, 76087
United States, Utah
Retina Associates of Utah
Salt Lake City, Utah, United States, 84107
United States, Virginia
Eye Surgeons of Richmond Inc. dba Virginia Eye Institute
Richmond, Virginia, United States, 23226
Retina Institute of Virginia
Richmond, Virginia, United States, 23235
Virginia Retina Center
Warrenton, Virginia, United States, 20186
United States, Washington
Retina Center Northwest
Silverdale, Washington, United States, 98383
Spokane Eye Clinical Research
Spokane, Washington, United States, 99204
United States, West Virginia
West Virginia University Eye Institute
Morgantown, West Virginia, United States, 26506
United States, Wisconsin
University of Wisconsin
Madison, Wisconsin, United States, 53792
Argentina
Organizacion Medica de Investigacion
Buenos Aires, Argentina, C1015ABO
Fundacion Zambrano
Caba, Argentina, 1023
Oftar
Mendoza, Argentina, M5500GGK
Microcirugía Ocular S.A
Rosario, Argentina, S2000CTC
Grupo Laser Vision
Rosario, Argentina, S2000DLA
Australia, New South Wales
Eyeclinic Albury Wodonga
Albury, New South Wales, Australia, 2640
Marsden Eye Research Centre
Parramatta, New South Wales, Australia, 2150
Save Sight Institute
Sydney, New South Wales, Australia, 2000
Sydney West Retina
Westmead, New South Wales, Australia, 2145
Austria
Kepler Universitätskliniken GmbH - Med Campus III; Abt. für Augenheilkunde
Linz, Austria, 4021
Belgium
CHU Brugmann (Victor Horta)
Bruxelles, Belgium, 1020
UZ Gent
Gent, Belgium, 9000
UZ Leuven Sint Rafael
Leuven, Belgium, 3000
CHU Sart-Tilman
Liège, Belgium, 4000
Canada, Alberta
Calgary Retina Consultants
Calgary, Alberta, Canada, T2J 0C8
Canada, British Columbia
University of British Columbia
Vancouver, British Columbia, Canada, V6T 1Z4
Canada, Nova Scotia
QEII - HSC Department of Ophthalmology
Halifax, Nova Scotia, Canada, B3H 2Y9
Canada, Ontario
University of Ottawa Eye Institute
Ottawa, Ontario, Canada, K1H 8L6
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada, M4N 3M5
St. Michael'S Hospital
Toronto, Ontario, Canada, M5G 2C4
University Health Network Toronto Western Hospital
Toronto, Ontario, Canada, M5T 2S8
Canada, Quebec
Institut De L'Oeil Des Laurentides
Boisbriand, Quebec, Canada, J7H 1S6
Denmark
Sjællands Universitetshospital, Roskilde; Øjenafdelingen
Roskilde, Denmark, 4000
France
Chi De Creteil; Ophtalmologie
Creteil, France, 94010
Centre Odeon; Exploration Ophtalmologique
Paris, France, 75006
Hopital Lariboisiere; Ophtalmologie
Paris, France, 75010
Centre Ophtalmologique; Imagerie et laser
Paris, France, 75015
Ch Pitie Salpetriere; Ophtalmologie
Paris, France, 75651
CHU Poitiers - CHR La Miletrie; Ophtalmologie
Poitiers, France, 86021
Germany
Universitäts-Augenklinik Bonn
Bonn, Germany, 53127
Universitätsmedizin Göttingen Georg-August-Universität; Klinik für Augenheilkunde
Göttingen, Germany, 37075
Medizinische Hochschule Hannover, Klinik für Augenheilkunde
Hannover, Germany, 30625
Universitätsklinikum Köln; Augenklinik
Köln, Germany, 50937
Universitätskliniikum Schleswig-Holstein, Campus Lübeck, Klinik für Augenheilkunde
Lübeck, Germany, 23538
Augenabteilung am St. Franziskus-Hospital
Münster, Germany, 48145
Universitätsklinikum Münster; Augenheilkunde
Münster, Germany, 48149
Hungary
Budapest Retina Associates Kft.
Budapest, Hungary, 1133
Debreceni Egyetem Klinikai Kozpont; Szemeszeti Klinika
Debrecem, Hungary, 4032
Ganglion Medial Center
Pecs, Hungary, 7621
Italy
Fondazione Ptv Policlinico Tor Vergata Di Roma;U.O.S.D. Patologie Renitiche
Roma, Lazio, Italy, 00133
Fondazione G.B. Bietti Per Lo Studio E La Ricerca in Oftalmologia-Presidio Ospedaliero Britannico
Roma, Lazio, Italy, 00198
Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico-Clinica Regina Elena;U.O.C Oculistica
Milano, Lombardia, Italy, 20100
Azienda Ospedaliero Universitaria Di Sassari;U.O. Oculistica
Sassari, Sardegna, Italy, 07100
Mexico
Macula Retina Consultores
Mexico, D.F., Mexico, 01120
Hospital de la Ceguera APEC
Mexico, D.F., Mexico, 04030
Netherlands
Academisch Medisch Centrum Universiteit Amsterdam
Amsterdam, Netherlands, 1105 AZ
Leids Universitair Medisch Centrum
Leiden, Netherlands, 2333 ZA0
Radboud University Nijmegen Medical Centre; Ophthalmology
Nijmegen, Netherlands, 6525 EX
Peru
CLINICA RICARDO PALMA; Oftalmologos Contreras
Lima, Peru, 27
Clinica Anglo Americana
Lima, Peru, Lima 27
Poland
OFTALMIKA Sp. z o.o
Bydgoszcz, Poland, 85-631
Optimum Profesorskie Centrum Okulistyki
Gdańsk, Poland, 80-809
Gabinet Okulistyczny Prof Edward Wylegala
Katowice, Poland, 40-594
SP ZOZ Szpital Uniwersytecki w Krakowie Oddział Kliniczny Okulistyki i Onkologii Okulistycznej
Krakow, Poland, 31-501
Slovakia
Nemocnica sv. Michala, a.s.
Bratislava, Slovakia, 81108
Fakultna nemocnica Trencin Ocna klinika
Trencin, Slovakia, 911 71
Fakultna nemocnica s poliklinikou Zilina; Ocne oddelenie
Zilina, Slovakia, 012 07
Spain
Hospital Universitari de Bellvitge; Servicio de Oftalmologia
Hospitalet De Llobregat, Barcelona, Spain, 8907
Hospital General de Catalunya
San Cugat Del Valles, Barcelona, Spain, 08195
Instituto Clinico Quirurgico de Oftalmologia - ICQO
Bilbao, Guipuzcoa, Spain, 48006
VISSUM Instituto Oftalmológico de Alicante
Alicante, Spain, 03016
Institut de la Macula i la retina
Barcelona, Spain, 08022
FISABIO. Fundación Oftalmologica del Mediterraneo
Valencia, Spain, 46015
Hospital Universitario Rio Hortega; Servicio de Oftalmologia
Valladolid, Spain, 47012
Switzerland
Stadtspital Triemli; Augenklinik
Zürich, Switzerland, 8063
United Kingdom
Ayr Hospital
AYR, United Kingdom, KA6 6DX
The Princess Alexandra Eye Pavilion
Edinburgh, United Kingdom, EH3 9HA
Frimley Park Hospital
Frimley, United Kingdom, GU16 7UJ
Royal Hallamshire Hospita
Sheffield, United Kingdom, S10 2JF
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche
  Study Documents (Full-Text)

Documents provided by Hoffmann-La Roche:
Statistical Analysis Plan  [PDF] October 2, 2017
Study Protocol  [PDF] September 24, 2015


Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT02247479    
Other Study ID Numbers: GX29176
2014-000107-27 ( EudraCT Number )
First Posted: September 25, 2014    Key Record Dates
Results First Posted: April 23, 2019
Last Update Posted: June 26, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Geographic Atrophy
Atrophy
Retinal Degeneration
Retinal Diseases
Eye Diseases
Pathological Conditions, Anatomical
Immunoglobulin Fab Fragments
Immunologic Factors
Physiological Effects of Drugs